Top Page
Vita Life Sciences Limited
(Sydney:VLS)
Vita Life Sciences Limited (VLS) vs. iShares MSCI Australia ETF (EWA)
Vita Life Sciences Limited Business Overview & Revenue Model
Vita Life Sciences Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 79.50M | 74.16M | 66.89M | 57.10M | 46.48M | Gross Profit |
| 47.24M | 42.60M | 39.74M | 34.81M | 29.27M | EBIT |
| 11.66M | 12.21M | 10.77M | 11.31M | 8.32M | EBITDA |
| 13.46M | 13.10M | 11.37M | 11.71M | 8.88M | Net Income Common Stockholders |
| 8.78M | 9.08M | 7.08M | 8.29M | 6.09M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 28.60M | 24.63M | 15.69M | 15.89M | 14.48M | Total Assets |
| 71.89M | 59.81M | 51.80M | 45.27M | 39.10M | Total Debt |
| 517.00K | 387.00K | 601.00K | 373.00K | 2.07M | Net Debt |
| -28.08M | -24.24M | -15.09M | -15.52M | -12.40M | Total Liabilities |
| 19.61M | 16.48M | 15.30M | 14.85M | 14.66M | Stockholders Equity |
| 52.35M | 43.40M | 36.57M | 30.75M | 24.72M |
| Cash Flow | Free Cash Flow | |||
| 5.96M | 12.32M | 7.54M | 5.73M | 7.46M | Operating Cash Flow |
| 6.16M | 12.98M | 7.68M | 5.89M | 7.54M | Investing Cash Flow |
| -198.00K | -660.00K | -139.00K | -155.00K | -89.00K | Financing Cash Flow |
| -2.99M | -2.88M | -3.10M | -4.39M | -3.03M |
Vita Life Sciences Limited Technical Analysis
Vita Life Sciences Limited Peers Comparison
Vita Life Sciences Limited Corporate Events
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program. As of June 5, 2025, the company has bought back a total of 5,759 ordinary fully paid securities, with 454 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, where it recently bought back 5,305 ordinary fully paid securities. This buy-back initiative is part of the company’s strategy to optimize its capital structure and enhance shareholder value, reflecting a proactive approach to managing its financial resources and reinforcing its market position.
Vita Life Sciences Limited has announced a new on-market buy-back of its ordinary fully paid securities, as indicated by its ASX security code VLS. This strategic move is likely aimed at optimizing the company’s capital structure and potentially enhancing shareholder value, reflecting a proactive approach to managing its financial resources.
Vita Life Sciences Limited announced that all resolutions proposed at its 2025 Annual General Meeting were successfully passed. Key resolutions included the approval of the remuneration report, the re-election of Director Mr. Henry Townsing, an increase in the aggregate annual remuneration for non-executive directors, and a share buy-back initiative. These decisions reflect the company’s strategic direction and commitment to enhancing shareholder value, potentially impacting its financial strategies and governance structure.
Vita Life Sciences Limited has announced the final notification of its on-market buy-back program, purchasing a total of 1,218,581 ordinary fully paid securities for a consideration of AUD 2,309,095.17. This buy-back reflects the company’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in its financial health.
Vita Life Sciences Limited has announced an update regarding its ongoing buy-back program, where a total of 1,218,101 securities have been bought back prior to the previous day, with an additional 86 securities bought back on the previous day. This buy-back initiative reflects the company’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in its financial stability.
Vita Life Sciences Limited has announced a daily update on its ongoing on-market buy-back program. As of the latest update, the company has repurchased a total of 1,218,101 ordinary fully paid securities. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited announced a change in the director’s interest, with Director Peter Osborne acquiring 11,090 ordinary shares through an on-market trade, increasing his total holdings to 41,184 shares. This acquisition reflects a potential vote of confidence in the company’s future prospects and could positively influence stakeholder perceptions regarding the company’s market position and operational strategies.
Vita Life Sciences Limited has announced an update regarding its ongoing share buy-back program. As of May 6, 2025, the company has repurchased a total of 1,152,511 ordinary fully paid securities, with 15,999 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 1,120,907 securities have been bought back before the previous day, with an additional 15,605 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, reporting the acquisition of 34,395 ordinary fully paid securities on the previous day. This buy-back initiative, which began in May 2024, aims to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of outstanding shares.
Vita Life Sciences Limited has announced its 2025 Annual General Meeting (AGM) scheduled for May 22, 2025, at their Mascot, NSW location. Shareholders are invited to attend in person or observe via a webinar conferencing facility. The company has provided details on how shareholders can access meeting materials online and submit proxy votes, emphasizing the importance of shareholder participation in the voting process. This meeting is a key event for stakeholders to engage with the company’s strategic direction and governance.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program. The company reported the buy-back of 50,000 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 986,512. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced a daily update on its ongoing share buy-back program, highlighting the purchase of 12,240 ordinary fully paid securities on the previous day. This buy-back initiative, which began on May 22, 2024, reflects the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 17,760 ordinary fully paid securities were bought back on the previous day, adding to the cumulative total of 956,512 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.
Vita Life Sciences Limited has announced an update regarding its ongoing buy-back program, with a total of 946,963 securities bought back before the previous day and an additional 9,549 securities purchased on the previous day. This buy-back initiative reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value, indicating a proactive approach to financial management and market positioning.
Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, revealing the acquisition of 10,451 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 936,512. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Vita Life Sciences Limited has announced that its Annual General Meeting (AGM) will be held on 22 May 2025, with the re-election and appointment of directors as a key agenda item. The deadline for director nominations is set for 27 March 2025, indicating the company’s ongoing governance and leadership planning efforts.